What happens when you remove the macrophages that help guard a lymph node? Four studies offer a useful starting point. Together, they show how clodronate liposomes can help researchers explore viral capture, vaccine responses, and natural killer cell activation—and why dose, delivery route, and timing matter.
Why these macrophages matter
Lymph nodes filter lymph and help coordinate immune responses. Macrophages in the subcapsular sinus sit near the entry point for incoming lymph, where they capture particles and interact with nearby immune cells. Medullary sinus macrophages form another population deeper in the node.
Depleting these cells can help reveal their contribution to a response. The important question is which cells are removed under a given set of conditions. The studies below illustrate how researchers checked depletion and connected it to biological outcomes.
Removing the viral capture layer
In a study of lymph-borne viruses, mice received a single 30 µL subcutaneous injection of clodronate liposomes into the hind footpad, 7–10 days before the experiment. The liposomes were prepared with clodronate supplied by Roche Diagnostics and phosphatidylcholine supplied by LIPOID. Researchers then examined draining popliteal lymph nodes using tissue staining, flow cytometry, and electron microscopy.
Clodronate liposome treatment reduced CD169-positive macrophages in the draining popliteal lymph node. The original panels compare untreated and treated tissue and the frequencies of lymph node cell populations. Source: Junt et al., Nature, 2007.
Checking the surrounding lymph node structure
Histology and electron microscopy provide additional views of the treated lymph node. The tissue organization remained broadly intact despite macrophage depletion. Source: Junt et al., Nature, 2007.
The treatment depleted subcapsular CD169-positive macrophages, while LYVE-1-positive lymphatic endothelial cells and CD11c-high cortical dendritic cells were largely preserved. The lymph node architecture also remained broadly intact. These checks helped distinguish macrophage depletion from a general disruption of the tissue.
Dose changes which macrophages are depleted
A separate study compared intravenous clodronate liposomes at 6.5 mg/kg and 40 mg/kg, with depletion assessed 24 hours later by flow cytometry and tissue imaging. Both doses reduced CD169-positive subcapsular macrophages. The higher dose also depleted F4/80-positive macrophages, making it a broader intervention.
Flow cytometry shows a reduction in CD169-positive cells after low-dose and high-dose clodronate treatment. CTRL, control; LD, low dose; HD, high dose. Source: CD169+ Subcapsular Macrophage Role in Antigen Adjuvant Activity, Frontiers in Immunology, 2021.
A narrower depletion model for studying adjuvants
F4/80 staining and tissue imaging show that the low dose largely spared F4/80-positive macrophages, while the high dose depleted both populations. This difference makes dose selection important when attributing a response to a specific macrophage population. Source: Frontiers in Immunology, 2021.
The low-dose model helped separate the role of the subcapsular macrophage population from the wider effects of macrophage depletion. In the adjuvant systems tested, removing these cells impaired follicular dendritic cell responses and antigen-specific antibody responses. The study also compared depletion with loss of the CD169 molecule itself, helping distinguish the function of the cells from the function of that marker.
The practical lesson is straightforward: a lower dose and a higher dose can answer different questions. Confirming which populations remain is as important as confirming that the target population has been reduced.
Testing the role of macrophages in QS-21 activity
Another study examined QS-21, a component of the AS01 adjuvant system. Female C57BL/6 mice, 6–12 weeks old, received clodronate liposomes or control liposomes by intramuscular injection six days before immunization. Antigens included 4 µg hepatitis B surface antigen or 1 µg ovalbumin, formulated with 1 µg QS-21. The design allowed researchers to test the response after macrophages had been depleted from the draining lymph node.
Six days after liposome treatment, CD169-positive macrophages were depleted in the draining lymph node, while the non-draining node was preserved. The accompanying plots show no significant changes in the measured monocyte, neutrophil, and dendritic cell counts at this depletion-validation time point. Source: Detienne et al., Scientific Reports, 2016.
This spatially restricted depletion helped the researchers investigate the contribution of lymph node resident macrophages to QS-21 activity. In the study, depletion reduced subsequent QS-21-induced innate cell recruitment and antigen-specific immune responses. The result links the macrophage population to the adjuvant response, rather than simply to its presence in the tissue.
It also highlights a useful distinction: cell counts measured when validating depletion describe the starting condition. Recruitment measured after immunization describes the response to the adjuvant. Those are different readouts and should be interpreted separately.
Connecting macrophages to NK cell activation
In a Toxoplasma gondii infection model, clodronate liposomes or PBS-containing control liposomes were injected into the footpad 8–9 days before infection. Researchers then examined lymph node cell populations and natural killer (NK) cell responses.
Clodronate treatment reduced CD169-positive cell populations and lowered NK cell IFN-γ production and CD69 expression. NK cell abundance and the infection index did not differ significantly in the comparisons shown. Source: Coombes et al., Cell Reports, 2012.
Depletion reduced CD169-positive subcapsular macrophages and a CD169-positive Ly6C-positive population. Some other myeloid populations were less affected. Although the total NK cell population was not significantly reduced, NK cell activation was lower, as measured by IFN-γ and CD69. The findings support a role for CD169-positive macrophages in activating NK cells during this infection model.
What to take from these studies
Clodronate liposomes can help connect a lymph node macrophage population to a specific immune function. Across these examples, the clearest conclusions came from pairing functional measurements with checks on the depleted cells, neighboring populations, and tissue structure. Dose, injection route, and the interval before analysis shaped the depletion pattern in each model.
YEASEN products for macrophage depletion studies
YEASEN offers clodronate liposomes, PBS-containing control liposomes, and paired kits for macrophage depletion research. The paired kit includes depletion and control formulations for comparative studies.
|
Cat. No. |
Product |
Pack size |
|
40337ES |
Clodronate Liposomes |
2 mL / 5 mL / 10 mL |
|
40338ES |
Control Liposomes |
2 mL / 5 mL / 10 mL |
|
Clodronate Liposomes Kit |
2 + 2 mL / 5 + 5 mL / 10 + 10 mL |
From macrophage isolation and phenotyping to depletion models, functional studies, and immune assays, YEASEN supports researchers across the macrophage research workflow.
Reference
[1] Junt et al. Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature, 2007. doi:10.1038/nature06287.
[2] CD169+ Subcapsular Macrophage Role in Antigen Adjuvant Activity. Frontiers in Immunology, 2021. doi:10.3389/fimmu.2021.624197.
[3] Detienne et al. Central Role of CD169+ Lymph Node Resident Macrophages in the Adjuvanticity of the QS-21 Component of AS01. Scientific Reports, 2016. doi:10.1038/srep39475.
[4] Coombes et al. Infection-Induced Regulation of Natural Killer Cells by Macrophages and Collagen at the Lymph Node Subcapsular Sinus. Cell Reports, 2012. doi:10.1016/j.celrep.2012.06.001.